Our portfolio company Vincere Biosciences just received a $2.7 million NIH SBIR Phase II award to advance its USP30 inhibitor through IND-enabling studies for AKI.
Over 13 million people suffer acute kidney injury every year. Zero approved therapies directly modify the disease.
Funding the future first, before the world catches up. Early-stage VC firm.

